Endocrine Abstracts

Objective

Scanty data about glucose metabolism, hypertension and metabolic syndrome (MS) have been reported in Paget’s disease of bone (PDB) to be related with increased cardiovascular mortality. We aimed to determine prevalence of metabolic syndrome in PDB and to determine the relationship between metabolic syndrome and bone-specific alkaline phosphatase levels.

Patients and methods

Twenty three patients with PDB and 23 age, sex and body mass index (BMI) matched controls were recruited to the study from the outpatient clinics of Endocrinology. All participants were evaluated using the International Diabetes Federation (IDF)-2006 metabolic syndrome criteria. Parameters of bone and mineral metabolism were assessed.

Results

Seventeen of 23 (%73) patients had MS while 8 of 29 (% 27) controls had metabolic syndrome. Difference between groups was statistically significant. Compared with controls, patients group had higher prevalance of anti-hypertensive medication usage and impaired glucose tolerance. While ALP level was statistically higher in patients group, calcium, phosphate, albumin and HDL levels were lower in patients (P < 0.05). There was a significant correlation between ALP level and hypertension medication (P = 0.0045, r = 0.27).

Conclusion

To the best of our knowlegde, this is the first study evaluating the prevalance of MS in patients with PDB. The result of this study indicate that individuals with PDB may also exhibit metabolic disturbances associated with cardiovascular risk. Therefore, these patients should also be regularly monitored for metabolic syndrome.